Markovic Srdjan, Jankovic Marijana, Kalaba Ana, Zogovic Branimir, Sreckovic Slobodan S
Gastroenterology and Hepatology, University Hospital Medical Center "Zvezdara", Belgrade, SRB.
Department of General Surgery, Royal Prince Alfred Hospital, New South Wales, AUS.
Cureus. 2021 Oct 25;13(10):e19019. doi: 10.7759/cureus.19019. eCollection 2021 Oct.
Relapses in inflammatory bowel disease (IBD) complicated by infection (CDI) are associated with significant morbidity and mortality. CDI can exacerbate the course of IBD and may result in prolonged hospitalizations, admissions to intensive care, surgical interventions, or even death. Early detection and aggressive treatment with systemic corticosteroids or biologics such as infliximab are often needed in severe presentations. Five cases of relapsed ulcerative colitis complicated by fulminant CDI were retrospectively reviewed. Biological therapy with infliximab was initiated upon multidisciplinary team assessment as the cases were resistant to standard IBD therapy. All five patients improved clinically and avoided early surgical intervention. Some required prolonged therapy with infliximab to achieve remission. Early recognition of CDI and aggressive therapy with biologics may be required to avoid complications in the IBD patients experiencing a relapse. Infliximab therapy should be considered early on, especially where the disease is resistant to standard therapy.
炎症性肠病(IBD)合并艰难梭菌感染(CDI)后的复发与显著的发病率和死亡率相关。CDI可使IBD病情恶化,并可能导致住院时间延长、入住重症监护病房、接受手术干预,甚至死亡。在严重病例中,通常需要早期检测并用全身性皮质类固醇或生物制剂(如英夫利昔单抗)进行积极治疗。回顾性分析了5例复发性溃疡性结肠炎合并暴发性CDI的病例。由于这些病例对标准IBD治疗耐药,经多学科团队评估后启动了英夫利昔单抗生物治疗。所有5例患者临床症状均有改善,避免了早期手术干预。部分患者需要长期使用英夫利昔单抗治疗以实现缓解。对于复发的IBD患者,可能需要早期识别CDI并用生物制剂进行积极治疗以避免并发症。应尽早考虑使用英夫利昔单抗治疗,尤其是在疾病对标准治疗耐药的情况下。